Tarveda Raises $30 Million Series D Financing

Boston – February 2, 2017 – Cooley advised Tarveda Therapeutics on its $30 million Series D financing round. New investor Versant Ventures led the round, which also included existing investors New Enterprise Associates, Novo A/S, NanoDimension and Flagship Pioneering.

Tarveda plans to use the funding, in addition to the $38 million raised in its Series C financing in 2016, to advance its novel Pentarin platform.

Tarveda discovers and develops Pentarins, a new class of potent and selective miniaturized drug conjugates with enhanced targeting capabilities for the treatment of solid cancer tumors. Tarveda’s lead Pentarin drug candidate, PEN-221, is a miniaturized drug conjugate that targets the somatostatin receptor 2 for treatment of patients with neuroendocrine and small cell lung cancers.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Marc Recht Partner, Boston
Joshua Rottner Partner, Boston
Wilber A. Barillas Associate, Boston
Michael Rohr Associate, Boston
Marjorie Wagman Special Counsel, Palo Alto